Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Bristol-Myers, Nitto Ink NASH, Fibrosis Deal
Investopedia
Mon, 11/14/16 - 09:53 am
Bristol-Myers Squibb
Nitto
NASH
fibrosis
Bristol-Myers pens $100M NASH, fibrosis drug deal with Japan’s Nitto
Fierce Biotech
Fri, 11/11/16 - 09:52 am
Bristol-Myers Squibb
M&A
NASH
fibrosis
Japan
Nitto
The development landscape for Non-Alcoholic Steatohepatitis (NASH)
BioPharma Dive
Thu, 11/10/16 - 10:20 am
NASH
drug development
Covance
CROs
Good and bad news for Gilead
BioPharma Dive
Sat, 10/22/16 - 03:13 pm
Gilead Sciences
selonsertib
HIV
hepatitis C
NASH
Gilead Fatty Liver Drug Advances to Phase 3
Investopedia
Fri, 10/21/16 - 10:05 am
Gilead Sciences
non-alcoholic fatty liver disease
NASH
selonsertib
Allergan May Have Outbid Gilead For Tobira, Setting The Backdrop For A Showdown In NASH
Seeking Alpha
Wed, 10/19/16 - 10:44 am
Allergan
Gilead Sciences
Tobira
NASH
Cenicriviroc
Allergan Enters the Attractive NASH Market
Market Realist
Thu, 10/6/16 - 09:26 am
Allergan
NASH
Cenicriviroc
Tobira Therapeutics
Cempra Releases Promising Phase II Clinical Trial Results For Anti-NASH Drug
Xtalks
Wed, 10/5/16 - 05:25 pm
Cempra
clinical trials
NASH
liver disease
Solithromycin
Biotech: Why NASH is So Hot Right Now
Barron's
Wed, 09/21/16 - 10:55 pm
NASH
Allergan
M&A
Gilead Sciences
Tobira Therapeutics
Galmed Pharmaceuticals
Allergan just acquired two companies in one day
Yahoo/Business Insider
Tue, 09/20/16 - 08:54 pm
Allergan
M&A
liver disease
NASH
Akarna Therapeutics
Tobira Therapeutics
Allergan pays $50 mln to buy privately-held Akarna Therapeutics
Marketwatch
Tue, 09/20/16 - 08:42 pm
Allergan
Akarna Therapeutics
M&A
NASH
Allergan Buys Tobira for Up to $1.7 Billion to Gain Liver Drug
Bloomberg
Tue, 09/20/16 - 08:56 pm
Allergan
Tobira Therapeutics
M&A
NASH
Gilead Sciences Is On The Cusp Of A Breakthrough In NASH
Seeking Alpha
Mon, 06/13/16 - 10:31 am
Gilead Sciences
NASH
Inside Gilead Sciences’ Active Involvement in Drugs for NASH
Yahoo/Market Realist
Thu, 05/12/16 - 09:44 am
Gilead Sciences
NASH
simtuzumab
GS-4997
GS-9674
Gilead bags early-stage NASH drug in $1.2B Nimbus deal
Fierce Biotech
Mon, 04/4/16 - 09:48 am
Gilead Sciences
NASH
Nimbus
Can Gilead Sciences Save Key Pipeline Blockbusters from Rivals?
Bidness, ETC
Sat, 01/2/16 - 10:16 am
Gilead Sciences
simtuzumab
NASH
JAK inhibitors
filgotinib
Genfit launches a PhIII study for NASH drug
Fierce Biotech
Tue, 11/17/15 - 09:09 am
Genmit
NASH
elafibranor
clinical trials
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Wed, 10/28/15 - 09:23 am
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA
Gilead's Next Logical Acquisition, Part 1: NASH And Galmed
Seeking Alpha
Thu, 10/8/15 - 12:21 pm
Gilead Sciences
M&A
Galmed Pharmaceuticals
NASH
Raptor Pharmaceutical's Trial Failed, But Huntington's Disease Update Could Bring Gains At Year End
Yahoo/Benzinga
Tue, 09/15/15 - 11:40 am
Raptor Pharmaceutical
RP103
NASH
Huntington's disease
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
next ›
last »